Abstract

Tadalafil is a phosphodiesterase type-5 (PDE5) inhibitor licensed for the treatment of erectile dysfunction (ED) in adult males (Cialis—Lilly) and for the management of pulmonary arterial hypertension (Adcirca—Lilly).¹ The 5mg tablet was licensed in November 2012 for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) in adult males (Cialis 5mg—Lilly).² In this article, we consider the evidence for tadalafil and how its use fits with current management strategies for BPH.